Celiprolol Hydrochloride

57470-78-7 Categories: , ,
  • # LGM Pharma is a Celiprolol Hydrochloride CAS# 57470-78-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Celiprolol Hydrochloride
  • CAS #: 57470-78-7
  • DrugBank: DB04846
  • Formula: C20-H33-N3-O4.Cl-H
  • Molecular Mass: 415.959
  • Synonyms: 3-(3-Acetil-4-(3-tert-butilamino-2-hidroxipropoxi)fenil)-1,1-dietilurea HCl, 3-(3-Acetil-4-(3-tert-butilamino-2-hidroxipropoxi)fenil)-1,1-dietilurea HCl [Spanish], 3-(3-Acetyl-4-(3-(tert-butylamino)-2-hydroxypropoxy)phenyl)-1,1-diethylurea monohydrochloride, 3-(3-Acetyl-4-(3-tert-butylamino-2-hydroxypropoxy)phenyl)-1,1-diethylharnstoff HCl, 3-(3-Acetyl-4-(3-tert-butylamino-2-hydroxypropoxy)phenyl)-1,1-diethylharnstoff HCl [German], 3-(3-Acetyl-4-(3-tert-butylamino-2-hydroxypropoxy)phenyl)-1,1-diethylurea hydrochloride, CCRIS 1095, Celiprolol clorhidrato, Celiprolol clorhidrato [Spanish], Celiprolol HCl, Celiprolol hydrochlorid, Celiprolol hydrochlorid [German], Celiprolol hydrochloride, Clorhidrato de celiprolol, Clorhidrato de celiprolol [Spanish], EINECS 260-752-2, Selecor, Selectrol, St 1396, UNII-G1M3398594, Urea, N'-(3-acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethyl-, monohydrochloride
  • SMILES: c1(c(cc(NC(N(CC)CC)=O)cc1)C(C)=O)OC[C@@H](CNC(C)(C)C)O.Cl
  • InChl: 1S/C20H33N3O4.ClH/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6;/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26);1H
  • General Reference:

    Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, Fauret AL, Fiessinger JN, Germain DP, Georgesco G, Hulot JS, De Paepe A, Plauchu H, Jeunemaitre X, Laurent S, Boutouyrie P: Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010 Oct 30;376(9751):1476-84. doi: 10.1016/S0140-6736(10)60960-9. Epub 2010 Sep 7. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements
This website uses cookies. By using our site, you agree to our terms of service